Skip to content

Study · Animal study (in vivo) · rat · 2023

6 results

Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats.

Smoday IM, Krezic I, Kalogjera L, Vukovic V, Zizek H, Skoro M, Kovac KK, Vranes H, Barisic I, Sikiric S, Strbe S, Tepes M and 16 more

Show all authors

Oroz K, Zubcic S, Stupnisek M, Beketic Oreskovic L, Kavelj I, Novosel L, Prenc M, Barsic Ostojic S, Dobric I, Sever M, Blagaic AB, Skrtic A, Staresinic M, Sjekavica I, Seiwerth S, Sikiric P

Pharmaceuticals (Basel, Switzerland)23 Oct 2023Cited by 11 (Europe PMC)

PMID37895979 (opens in a new tab)PMCIDPMC10610251 (opens in a new tab)DOI10.3390/ph16101507 (opens in a new tab)PepBankPUB-37895979
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

After inferior caval vein embolization therapy, post-embolization syndrome (sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein, assessment at 15, 30, 60 min, prime lung lesions, thromboemboli occluding lung vessels), as a severe occlusion/occlusion-like syndrome, might be resolved as a whole by stable gastric pentadecapeptide BPC 157 therapy. At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically). As before, confronted with the occlusion of major vessel(s) or similar noxious procedures, such as rapidly acting Virchow triad circumstances, the particular effect of the therapy (i.e., collateral pathways activation, "bypassing vascular key", i.e., direct blood flow delivery via activation of azygos vein) assisted in the recovery of the vessel/s and counteracted multiorgan failure due to occlusion/occlusion-like syndrome as a whole in the laurate-injected rats. Along with prime lung lesions and thromboemboli occluding lung vessels, post-embolization syndrome rapidly occurred peripherally and centrally as a shared multiorgan and vessel failure, brain, heart, lung, liver, kidney, and gastrointestinal tract lesions, venous hypertension (intracranial (superior sagittal sinus), portal, and caval), aortal hypotension, progressing thrombosis in veins and arteries and stasis, congested and/or failed major veins, and severe ECG disturbances. Whatever the cause, these were all counteracted, eliminated, or attenuated by the application of BPC 157 therapy. As recovery with BPC 157 therapy commonly and rapidly occurred, reversing the collapsed azygos vein to the rescuing collateral pathway might initiate rapid direct blood delivery and start blood flow reorganization. In conclusion, we suggest BPC 157 therapy to resolve further vascular and embolization injuries.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with sodium laurate-induced post-embolization syndrome, BPC‑157 therapy counteracted multiorgan failure due to occlusion-like syndrome as a whole.

    In plain wordsIn rats with a vein-blockage syndrome, BPC‑157 counteracted the damage to several organs at once.

    Peptide
    BPC-157
    Outcome
    DecreaseOcclusion-like syndrome and multiorgan failure
    Study

    ratn: not reported in source

    Sodium laurate-induced post-embolization syndrome (inferior caval vein embolization)
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    assisted in the recovery of the vessel/s and counteracted multiorgan failure due to occlusion/occlusion-like syndrome as a whole in the laurate-injected rats.
    3 context sentences
    Summary · context
    shared multiorgan and vessel failure, brain, heart, lung, liver, kidney, and gastrointestinal tract lesions
    Summary · context
    At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically).
    Summary · context
    sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats with sodium laurate-induced post-embolization syndrome, BPC‑157 therapy assisted the recovery of vessels through collateral pathway activation and direct blood flow delivery via the azygos vein.

    In plain wordsIn rats with a vein-blockage syndrome, BPC‑157 helped blood vessels recover by opening a side route for blood flow.

    Peptide
    BPC-157
    Outcome
    IncreaseVessel recovery and collateral (azygos vein) pathway
    Study

    ratn: not reported in source

    Sodium laurate-induced post-embolization syndrome (inferior caval vein embolization)
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    the particular effect of the therapy (i.e., collateral pathways activation, "bypassing vascular key", i.e., direct blood flow delivery via activation of azygos vein) assisted in the recovery of the vessel/s and counteracted multiorgan failure due to occlusion/occlusion-like syndrome as a whole in the laurate-injected rats.
    2 context sentences
    Summary · context
    At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically).
    Summary · context
    sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with sodium laurate-induced post-embolization syndrome, BPC‑157 therapy counteracted, eliminated or attenuated lung lesions and thromboemboli occluding lung vessels.

    In plain wordsIn rats with a vein-blockage syndrome, BPC‑157 reduced or removed lung damage and clots in lung vessels.

    Peptide
    BPC-157
    Outcome
    DecreaseLung lesions and thromboemboli occluding lung vessels
    Study

    ratn: not reported in source

    Sodium laurate-induced post-embolization syndrome (inferior caval vein embolization)
    Outcome group
    Cardiovascular events · Respiratory
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    Whatever the cause, these were all counteracted, eliminated, or attenuated by the application of BPC 157 therapy.
    3 context sentences
    Summary · context
    Along with prime lung lesions and thromboemboli occluding lung vessels
    Summary · context
    At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically).
    Summary · context
    sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with sodium laurate-induced post-embolization syndrome, BPC‑157 therapy counteracted, eliminated or attenuated venous hypertension (intracranial, portal, caval) and aortal hypotension.

    In plain wordsIn rats with a vein-blockage syndrome, BPC‑157 reduced or removed high vein pressure and low aortic pressure.

    Peptide
    BPC-157
    Outcome
    MixedVenous hypertension and aortal hypotension
    Study

    ratn: not reported in source

    Sodium laurate-induced post-embolization syndrome (inferior caval vein embolization)
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    Whatever the cause, these were all counteracted, eliminated, or attenuated by the application of BPC 157 therapy.
    3 context sentences
    Summary · context
    venous hypertension (intracranial (superior sagittal sinus), portal, and caval), aortal hypotension
    Summary · context
    At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically).
    Summary · context
    sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with sodium laurate-induced post-embolization syndrome, BPC‑157 therapy counteracted, eliminated or attenuated progressing venous and arterial thrombosis and stasis.

    In plain wordsIn rats with a vein-blockage syndrome, BPC‑157 reduced or removed clots in veins and arteries.

    Peptide
    BPC-157
    Outcome
    DecreaseProgressing thrombosis in veins and arteries and stasis
    Study

    ratn: not reported in source

    Sodium laurate-induced post-embolization syndrome (inferior caval vein embolization)
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    Whatever the cause, these were all counteracted, eliminated, or attenuated by the application of BPC 157 therapy.
    3 context sentences
    Summary · context
    progressing thrombosis in veins and arteries and stasis
    Summary · context
    At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically).
    Summary · context
    sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with sodium laurate-induced post-embolization syndrome, BPC‑157 therapy counteracted, eliminated or attenuated severe ECG disturbances.

    In plain wordsIn rats with a vein-blockage syndrome, BPC‑157 reduced or removed serious heart-tracing changes.

    Peptide
    BPC-157
    Outcome
    DecreaseSevere ECG disturbances
    Study

    ratn: not reported in source

    Sodium laurate-induced post-embolization syndrome (inferior caval vein embolization)
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    Whatever the cause, these were all counteracted, eliminated, or attenuated by the application of BPC 157 therapy.
    3 context sentences
    Summary · context
    severe ECG disturbances.
    Summary · context
    At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically).
    Summary · context
    sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.